Although all the articles in this issue of Perfusion are worth a read, I' d like to pick out some for your particular attention. I particularly like work that goes against the obvious expectation. When Murkin and others decided to look at acid-base management during bypass, 1 did they really expect to find that the protocol delivering less blood to the brain would be associated with less neurocognitive dysfunction? Once you know the answer, it's usually easy to invent reasons to explain it, but I would have expected pH-stat to minimise the cognitive injury that was of such concern to workers at the time. That, to me, would have been a no-brainer … and I would have been wrong.
In this issue of Perfusion, Miyamoto and colleagues report their experience of organ protection during aortic arch surgery. 2 My immediate thought while reading the abstract was that renal and hepatic outcomes are bound to be better when you perfuse the distal aorta. Of course, organs will be better protected from injury if they are perfused -it's another no-brainer! Admittedly, the study is not quite ideal in that it is a retrospective, observational study and not a randomised, controlled trial. On the other hand, it is from a single institution, with much of the practice standardised and consistent over the duration of data collection. It is the sort of study that will convince everyone in the institution concerned -how can you continue practices that your own data show are second best? -but leaves room for scepticism among disinterested parties. Let me summarise their work.
All patients included in the analysis underwent surgery with circulatory arrest for aortic arch aneurysm repair between 2009 and 2016. The main comparison is between 27 patients undergoing cerebral perfusion at 25°C and 25 patients having additional distal aortic perfusion at 28°C (a third group having cerebral perfusion only at 28°C comprised just 4 cases and so cannot contribute much to statistical testing). Eyeballing the plots showing renal and hepatic function, the 25°C group certainly seem to suffer more renal and hepatic injury (which is confirmed on statistical testing), but, surprisingly, the patients undergoing proximal perfusion only at 28°C seem to follow the outcome pattern of the 28°C dual-perfusion group rather than the 25°C proximal perfusion only patients. So, maybe temperature is the crucial variable, though just three degrees difference at that temperature will reflect a modest difference in metabolic rate (perhaps 48% of basal at 25°C and 57% of basal at 28°C) and the cooler patients should have better-preserved function. It doesn't quite make sense, but there were only four patients in the 28°C single perfusion group so I shouldn't read too much into it.
Dual perfusion is a more recent intervention and so there is a risk of historical bias here, of course. There is also the question of surgeon and patient effect when the study is not randomised. While the majority of new patients undergo dual perfusion at 28°C, we learn that some patients may still have proximal only perfusion at 25°C. Are these particularly high risk patients? Is this one surgeon's preference? It is a paper with tantalising results and a very measured discussion by the authors to help readers understand what conclusions can be drawn from their work. In fact, the evidence of benefit from the 'nobrainer' use of distal aortic perfusion during these cases is lacking in the world literature, with a 2012 Cochrane report 3 unable to find a randomised, controlled study into the question (and there hasn't been once since then, as far as I am aware). The conclusion of that review, based on observational work similar to this study, was that distal aortic perfusion may contribute to a reduction in spinal cord injury. However, at least one early study found that distal perfusion was associated with worse renal outcome, 4 perhaps by aggravating limb ischaemia and increasing myoglobinaemia. There are always risks to any intervention that may bring about benefit.
Later in this issue, Xue and colleagues have looked at pre-operative administration of thyroid hormone as a myocardial preconditioning agent before inducing cardiac ischaemia in rats. 5 There is already good evidence of this effect 6 and it stands to reason that the more you give, the greater the effect -another no-brainer! In fact, of course, there are obvious potential risks with thyroid hormones and this paper shows that the protective effect is greatest at the lowest dose. Once the dose is sufficient to activate the innate protective mechanisms, in this case probably by increasing expression of heat shock proteins, there is no benefit from increasing it. The effect of larger doses is dominated by the hormonal effect of thyroxine, which is detrimental to myocardial preservation. This is in contrast to the findings of volatile anaesthetics providing protection against cardiac No-brainers in medicine 796944P RF0010.1177/0267659118796944PerfusionEditorial editorial2018 Editorial ischaemia-reperfusion injury where, although there is no benefit from increasing doses, there is no detrimental effect either. 7 In fact, you can't really have too much anaesthetic -any anaesthetist will tell you that! Geoffrey Lockwood Section Editor, Perfusion
